Virginia opioid emergency declaration and expanded naloxone access

Virginia’s opioid emergency declaration and expanded access to emergency naloxone marked a public-health response to a crisis that had outgrown the systems meant to contain it. In late 2016, Levine issued a standing order making the overdose antidote available to all. The step broadened access to an immediate, potentially life-saving intervention, even as the account makes clear that reversing an overdose and securing ongoing treatment were separate challenges.

The declaration and its immediate purpose

The standing order was one element of Virginia’s response to escalating opioid harm. It made emergency naloxone more broadly available rather than limiting access to a narrow set of medical encounters. The declaration therefore had a practical consequence: it supported wider access to an intervention for an overdose already in progress. It did not, by itself, provide a treatment bed, an addiction clinician, or a dependable route from emergency stabilization to continuing care.

That distinction matters in the surrounding narrative. The state’s emergency response unfolded amid repeated overdose calls and growing pressure on hospitals and local services. An antidote could address the immediate danger, but survival after an overdose still depended on what happened next: whether a patient could reach a treatment provider, obtain medication, and remain connected to care.

Access beyond overdose reversal

The barriers to ongoing care were visible in individual treatment arrangements. Tess Henry, nearly seven months pregnant when she left jail in June 2015, spent a month with her mother before entering the Life Center of Galax, one of the few Virginia facilities that accepted patients using medication-assisted treatment. Private insurance covered most of the $20,000 cost, while her father paid the $6,500 deductible from the remainder of her college savings. Her case illustrates that treatment access could depend on family money, insurance, and finding a facility willing to continue medication rather than require its discontinuation.

Even after treatment was located, affordability remained a problem. Tess’s buprenorphine was mostly covered by insurance, but her addiction doctor required $700 up front and charged $90 to $100 for each follow-up visit, potentially as many as four in a month. Waiting lists further narrowed the route into care. At the time, federal rules capped the number of patients a certified Medication-assisted treatment prescriber could treat at 100; the cap was raised to 275 later that year. Wider access to emergency naloxone did not remove these financial and capacity constraints.

Building a route from crisis to care

Local efforts sought to connect people to treatment after an overdose or other crisis. The Hope Initiative developed a five-page spreadsheet listing thirty-six rehabilitation and aftercare providers across the southeastern United States, with volunteers matching referrals to patients’ finances and available beds. People could visit the Bradley Free Clinic on the second Monday of each month and, if they had no outstanding warrants, work with trained volunteers to navigate care. The program included help applying for Medicaid for those who qualified, while disagreement among some volunteers about medication-assisted treatment complicated the role of medication in the referral system.

Emergency-room staff also tried to establish a more direct handoff. Karen Kuehl studied Ontario protocols under which overdose patients were referred from emergency departments to outpatient medication-assisted treatment and counseling. Working with Hope Initiative coordinator Cheri Hartman, she pursued a similar arrangement in Roanoke, but provider shortages, insufficient detoxification and treatment beds, and bureaucratic, financial, and legal obstacles impeded it. A grant application offered hope of a smoother process; in the meantime, hospital social workers referred revived patients to Hope.

Later efforts continued to target this gap. Warren Bickel received a $1 million grant to pilot emergency-room-to-outpatient transfers linking overdose patients to buprenorphine, including through the newly approved once-monthly injection Sublocade. The project reflected the difference between making rescue medication more accessible and organizing sustained treatment after an overdose. Virginia’s emergency declaration widened one crucial point of access, while the work of building a dependable care pathway continued.

Unequal exposure and unequal protection

The emergency also sat within a longer history of unequal medical and criminal-justice responses. Don Wolthuis described heroin use in Roanoke during the 1980s and 1990s as a small, largely invisible group, widely understood as an inner-city, and therefore Black, drug. The account later notes that doctors prescribed painkillers to people of color at substantially lower rates than to white patients, amid distrust that they would misuse opioids. By 2014, overdose deaths among young white people had risen sharply from 2002 levels, while the death rate for people of color was relatively unchanged.

Yet the language of treatment and diversion did not apply evenly across the people caught up in drug enforcement. The call that arrest alone could not solve the crisis was often made in reference to predominantly white opioid users, while Ronnie Jones, imprisoned for armed heroin distribution, remained subject to a system in which Black and Hispanic people made up a disproportionate share of federal drug offenders. The emergency declaration and standing order expanded access to overdose reversal, but they did not erase these differences in exposure, punishment, or access to sustained care. The measure’s significance lies both in the immediate protection it offered and in the larger service and equity problems it could not resolve.